Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DISOPHROL vs ACTIDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Relief of symptoms of seasonal or perennial allergic rhinitis,Relief of symptoms of vasomotor rhinitis,Relief of nasal congestion associated with the common cold,Relief of sinusitis symptoms
Allergic rhinitis,Allergic conjunctivitis,Urticaria,Angioedema
1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
Terminal elimination half-life is 3-4 hours in adults; in renal impairment, half-life may be prolonged up to 8-12 hours requiring dose adjustment.
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Dexbrompheniramine is metabolized in the liver primarily via CYP450 enzymes; pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted largely unchanged in urine.
Hepatic via CYP450 isoenzymes (primarily CYP3A4 and CYP2D6); undergoes N-demethylation and N-oxidation.
Renal excretion of unchanged drug and metabolites; approximately 60-70% of a dose eliminated in urine as unchanged drug and glucuronide conjugates, with <10% in feces.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Approximately 50-60% bound to plasma proteins, primarily albumin.
Approximately 90% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 1.5-2.5 L/kg, indicating extensive tissue distribution.
2.5-4.0 L/kg, indicating extensive tissue distribution.
Oral bioavailability is about 70-80% due to first-pass metabolism.
Oral bioavailability is approximately 50-60% due to first-pass metabolism.
GFR 30-50 m L/min: administer every 6-8 hours. GFR 15-29 m L/min: administer every 12 hours. GFR <15 m L/min: not recommended.
GFR 10-50 m L/min: 2.5 mg every 6-8 hours; GFR <10 m L/min: 2.5 mg every 8-12 hours.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: use with caution, reduce dose frequency. Child-Pugh Class C: contraindicated.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Children 6-11 years: 1/2 tablet (3 mg dexbrompheniramine / 30 mg pseudoephedrine) orally every 4-6 hours, max 2 tablets per day. Children <6 years: not recommended.
Children 2-5 years: 1.25 mg orally every 4-6 hours (max 5 mg/day); Children 6-12 years: 1.25-2.5 mg every 4-6 hours (max 7.5 mg/day).
Initiate with 1/2 tablet every 6-8 hours; monitor for anticholinergic effects and hypertension; avoid in patients >65 years due to increased risk of adverse effects.
Initiate at 1.25 mg orally every 6-8 hours; maximum 5 mg per day due to increased risk of anticholinergic effects and renal impairment.
None.
None
Cardiovascular effects: may cause hypertension, palpitations, arrhythmias,Central nervous system stimulation: may cause insomnia, dizziness, tremor,Urinary retention: use with caution in patients with BPH or urinary obstruction,Increased intraocular pressure: avoid in narrow-angle glaucoma,Elderly patients: more sensitive to anticholinergic and cardiovascular effects
May cause drowsiness and impair mental alertness,Avoid alcohol and other CNS depressants,Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention,Elderly patients are more susceptible to anticholinergic effects
Severe hypertension,Coronary artery disease,Concurrent use of MAO inhibitors or within 14 days of such therapy,Narrow-angle glaucoma,Urinary retention,Severe renal impairment,Hypersensitivity to any component
Hypersensitivity to any component,Concurrent use with monoamine oxidase inhibitors
Avoid consuming alcohol while taking Disophrol. Caffeine may increase restlessness and insomnia. There is no specific food interaction, but taking with food may reduce gastrointestinal upset.
No specific food interactions, but taking with food may reduce GI side effects. Alcohol should be strictly avoided due to additive CNS depression. Grapefruit juice is not documented to interact.
DISOPHROL (dexchlorpheniramine/pseudoephedrine) is classified as FDA Pregnancy Category C. First trimester: Case reports suggest a possible small increased risk of gastroschisis with antihistamine use, but data are limited; pseudoephedrine may be associated with a small risk of gastroschisis and hemifacial microsomia. Second and third trimesters: No specific fetal risks have been clearly established; pseudoephedrine may cause fetal tachycardia and decreased uterine blood flow at high doses. Avoid in third trimester due to potential for uterine contraction inhibition and neonatal respiratory depression from antihistamines.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergic effects may cause neonatal tachycardia, irritability, and withdrawal symptoms if used near term.
DISOPHROL is excreted into breast milk. Dexchlorpheniramine: Present in low levels, M/P ratio not established; may cause irritability and drowsiness in infants. Pseudoephedrine: Excreted into breast milk with M/P ratio of approximately 2.6-3.5; may cause infant irritability and decreased milk production. Use caution and monitor infant for excessive drowsiness or irritability.
Excretion into breast milk likely but negligible amounts; no adverse effects reported in infants. M/P ratio not established. Considered compatible with breastfeeding; monitor for sedation or irritability in neonate.
No specific dose adjustments are recommended in pregnancy; however, use lowest effective dose and shortest duration. Due to increased plasma volume and renal clearance in pregnancy, pseudoephedrine may have reduced efficacy; dose may need empirical adjustment based on response. Avoid extended-release formulations in pregnancy.
No specific dose adjustments required in pregnancy; however, use lowest effective dose due to potential anticholinergic effects. Pharmacokinetics may be altered (increased volume of distribution), but no dose adjustment recommended.
Disophrol combines an antihistamine (dexbrompheniramine) and a decongestant (pseudoephedrine). Avoid in patients with hypertension, coronary artery disease, or hyperthyroidism due to pseudoephedrine's sympathomimetic effects. Monitor for anticholinergic side effects (drowsiness, dry mouth) from the antihistamine component. Use with caution in glaucoma, urinary retention, and prostatic hypertrophy.
ACTIDIL (triprolidine) is a first-generation antihistamine with sedative properties. Use cautiously in elderly due to risk of confusion, urinary retention, and falls. Avoid in patients with narrow-angle glaucoma, BPH, or asthma. Administer with food if GI upset occurs. Onset of action is 30-60 minutes; duration 4-6 hours.
Take this medication as prescribed; do not exceed recommended dose due to risk of serious side effects.,Avoid alcohol and other CNS depressants as they may increase drowsiness.,Do not take with other medications containing decongestants or antihistamines.,Notify your doctor if you have high blood pressure, heart disease, glaucoma, or difficulty urinating.,May cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.
Do not drive or operate heavy machinery until you know how this medication affects you; it can cause drowsiness.,Avoid alcohol and other CNS depressants, as they may increase sedation.,Take exactly as prescribed; do not exceed recommended dose.,If you miss a dose, skip it; do not double the next dose.,Notify your doctor if you experience blurred vision, difficulty urinating, or severe drowsiness.,Do not use for prolonged periods without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DISOPHROL vs ACTIDIL, answered by our medical review team.
DISOPHROL is a Antihistamine/Decongestant Combination that works by Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.. ACTIDIL is a Antihistamine that works by H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DISOPHROL and ACTIDIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DISOPHROL is: 1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.. The standard adult dose of ACTIDIL is: 2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DISOPHROL and ACTIDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DISOPHROL is classified as Category C. DISOPHROL (dexchlorpheniramine/pseudoephedrine) is classified as FDA Pregnancy Category C. First trimester: Case reports suggest a possible small increased risk of gastroschisis wi. ACTIDIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.